Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Clinical trial NCT01471210 · COMPLETED
Trial details
- NCT number
- NCT01471210
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-02-01
- Primary completion
- 2016-04-01
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.